Health Care·Pharmaceuticals·$547.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.68 | N/A | +2.07% |
management commentary, guidance changes, and full analysis available with Pro.
| +2.07% |
Tone: Cautiously Optimistic
Overall, management expressed confidence in the company's ability to navigate market challenges. They noted positive trends in consumer health and pharmaceuticals.
Management highlighted strong performance in key product lines.
They emphasized ongoing commitment to innovation and market expansion.
This earnings report shows that Johnson & Johnson managed to exceed expectations on EPS, indicating some resilience in their business. However, the lack of revenue data and guidance may leave investors uncertain about future performance. The stock reaction is not available, but the positive EPS surprise suggests some investor optimism.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CHARLES SCHWAB CORP
Oct 17, 2016